CAPLIPOINT2,792.00

Caplin Point Laboratories Ltd.

· Pharma & Health
₹ CrorePeersAJANTPHARMERISGLANDBLUEJETCONCORDBIOACUTAASEMCUREGRANULESMcap ₹21,219 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt1.20.60.60.6
Net Debt-375.5-510.2-479.3-479.3
Net Debt/Equity-0.16-0.18-0.13-0.13
Net Debt/EBITDA-0.68-0.79-0.63-0.60
Interest Coverage (EBIT/Interest)638.46952.41790.90790.90
Total Debt/Total Capital %0.050.020.020.02
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.